395 related articles for article (PubMed ID: 24177320)
1. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Xu R; Wang Q
J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
[TBL] [Abstract][Full Text] [Related]
2. Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection.
Xu R; Wang Q
BMC Bioinformatics; 2014 Jan; 15():17. PubMed ID: 24428898
[TBL] [Abstract][Full Text] [Related]
3. tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs.
Xu R; Wang Q
AMIA Annu Symp Proc; 2015; 2015():1342-51. PubMed ID: 26958275
[TBL] [Abstract][Full Text] [Related]
4. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
5. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
6. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
7. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
8. Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS.
Colilla S; Tov EY; Zhang L; Kurzinger ML; Tcherny-Lessenot S; Penfornis C; Jen S; Gonzalez DS; Caubel P; Welsh S; Juhaeri J
Drug Saf; 2017 May; 40(5):399-408. PubMed ID: 28155198
[TBL] [Abstract][Full Text] [Related]
9. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
11. Mining association patterns of drug-interactions using post marketing FDA's spontaneous reporting data.
Ibrahim H; Saad A; Abdo A; Sharaf Eldin A
J Biomed Inform; 2016 Apr; 60():294-308. PubMed ID: 26903152
[TBL] [Abstract][Full Text] [Related]
12. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
[TBL] [Abstract][Full Text] [Related]
13. Discovering clinical drug-drug interactions with known pharmacokinetics mechanisms using spontaneous reporting systems and electronic health records.
Jeong E; Su Y; Li L; Chen Y
J Biomed Inform; 2024 May; 153():104639. PubMed ID: 38583580
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
15. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
16. Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems.
Kreimeyer K; Menschik D; Winiecki S; Paul W; Barash F; Woo EJ; Alimchandani M; Arya D; Zinderman C; Forshee R; Botsis T
Drug Saf; 2017 Jul; 40(7):571-582. PubMed ID: 28293864
[TBL] [Abstract][Full Text] [Related]
17. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.
Xu R; Wang Q
J Biomed Inform; 2015 Jun; 55():64-72. PubMed ID: 25817969
[TBL] [Abstract][Full Text] [Related]
18. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database.
Shao Q; Xu Y; Li M; Chu X; Liu W
Eur J Clin Pharmacol; 2021 Aug; 77(8):1147-1156. PubMed ID: 34170370
[TBL] [Abstract][Full Text] [Related]
19. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
20. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants.
Wong CK; Ho SS; Saini B; Hibbs DE; Fois RA
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):731-7. PubMed ID: 26017154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
